Moderna, Inc. (MRNA) – Exploring mRNA therapeutics

Moderna, Inc. (MRNA) (Q2FY23)

Stock performance – The stock price showed a volatile trend in past 3 months. It declined by 10.98% during the period.

Moderna’s stock price declined by 16.81% in past 1-year. The stock has a 52-week high of $217.25 and its 52-week low is $95.02. In the past 3 years, the stock increased by 64%. MRNA has a 50-day moving Avg. and 200-day moving Avg. of $112.38 and $143.37, respectively.

Revenue Performance – MRNA revenue decreased by $4.4bn and $8.6bn, or 93% and 80%, for the three and six months ended June 30, 2023, respectively, compared to the same periods in 2022, mainly due to decreases in product sales of COVID-19 vaccine.

Company Guidance for FY23 – The Company is expecting 2023 COVID19 sales of $6bn to $8bn, dependent on U.S. vaccination rates. Total expected 2023 sales are comprised of ~$4 billion from existing APAs and $2bn to $4bn from additional sales to the U.S., Japan, EU and other countries. Sales will be subject to the timing of regulatory approvals, with the Company currently expecting a 2023 second half sales split of ~30% in the third quarter and 70% in the fourth quarter.

Highlights

MRNA is exploring mRNA therapeutics in the area of Immuno-oncology, Cardiovascular, Rare Disease and Autoimmune. In the realm of immuno-oncology, MRNA is researching and developing innovative therapies that harness the power of the immune system to combat cancer. mRNA-based immunotherapies.

This report is useful for M&A, business & investment analysis to all students, researchers, investors, private equity houses, broking firms, hedge funds, advisory firms and corporates to decide upon their investment strategies. Do connect with us, if you are looking for equity valuation, recommendation, analysis and market recommendation for any specific company, sector and industry.

Highlights

Valuation

– Enterprise Value
– CrispIdea Forecast
– Economic Value Added Analysis
– P/E Analysis
– Peer Valuation
– CrispIdea Forecast Relative to Consensus
– Consensus History and Surprise
– Consensus Momentum

Actual & Historical Performance

– Income Statement
– Balance Sheet
– Cash Flow
– 10 Year Historical Performance
– Ratio Analysis
– Segment Performance
– Key Developments
– M&A Deals

Peer Performance

– Summary
– Profitability
– Growth
– Price Performance

Ownership

Stock Price Performance

Crispidea Coverage

No of Pages: 33

To download the previous quarter’s equity/report CLICK HERE

To Download other equity/ stock reports CLICK HERE

Follow our LinkedIn page for more updates.